House Bill 75, known as the Pharmaceutical Full Disclosure Act, mandates that advertisements for prescription drugs and biological products include specific disclosures regarding the drug's approval date by the FDA, its market availability date, and detailed information about any side effects. This information must be derived from clinical trials, including the trial's duration, participant count, and the frequency of side effects experienced by participants. The goal of the bill is to enhance transparency and ensure consumers are fully informed about the medications they are considering.
If enacted, HB75 will amend Article 12 of Chapter 106 of the North Carolina General Statutes, establishing new requirements for pharmaceutical advertising within the state. This will likely lead to increased accountability for drug manufacturers and may influence how they market their products, potentially resulting in clearer communication of risks associated with prescription drugs. The law will apply to advertisements published in North Carolina starting October 1, 2025.
The general sentiment surrounding HB75 appears to be supportive among advocates for consumer rights and public health, who argue that increased transparency in pharmaceutical advertising is essential. However, there may be concerns from pharmaceutical companies regarding the potential burden of compliance and the implications for their marketing strategies.
Notable points of contention may arise from the pharmaceutical industry, which could argue that the requirements for disclosing detailed clinical trial information may be overly burdensome and could deter them from advertising their products effectively. Conversely, consumer advocacy groups may contend that the bill does not go far enough in protecting public health and ensuring that consumers have access to all necessary information.